Correction: Biglycan-driven risk stratification in ZFTA-RELA fusion supratentorial ependymomas through transcriptome profiling

Acta Neuropathologica Communications (2024) 13:4

10.1186/s40478-024-01921-w.

In this article [1], Fig. 1 appeared incorrectly and have now been corrected in the original publication. For completeness and transparency, the old incorrect versions are displayed below.

Fig. 1.

(a) Annotation onco-plot describing patient histological and molecular characteristics for target ZFTA-RELA ST-EPN tumors with available RNA sequencing data (n = 80). The following abbreviations were used: RT - radiotherapy, LOC - conformal local, CSP - craniospinal, PFS—progression-free survival, CNV—copy number variants. (b) Genomic locations the ZFTA-RELA fusion breakpoints stating the main types of the fusion. c, d) No survival differences were identified between the various ZFTA-RELA fusion types. d) Heatmap of significant differentially expressed genes between ZFTA-RELA fusion type 1 (n = 29) and 2 (n = 16)

Incorrect Fig. 1.

Correct Fig. 1.

Fig. 1.

(a) Annotation onco-plot describing patient histological and molecular characteristics for target ZFTA-RELA ST-EPN tumors with available RNA sequencing data (n = 80). The following abbreviations were used: RT - radiotherapy, LOC - conformal local, CSP - craniospinal, PFS—progression-free survival, CNV—copy number variants. (b) Genomic locations the ZFTA-RELA fusion breakpoints stating the main types of the fusion. c, d) No survival differences were identified between the various ZFTA-RELA fusion types. d) Heatmap of significant differentially expressed genes between ZFTA-RELA fusion type 1 (n = 29) and 2 (n = 16)